Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...

CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio When administered within 4 to 5 hours of ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

Review the side-effects of Alteplase as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...

Alteplase -- the only licensed therapy for acute ischemic stroke -- gives benefits in certain patients even when given after the conventional 3-hour treatment window. Phase III clinical trials of ...